68,300 Shares of Guardant Health, Inc. $GH Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 68,300 shares of the company’s stock, valued at approximately $12,182,000.

Several other hedge funds and other institutional investors also recently modified their holdings of GH. ABS Investment Management LLC bought a new position in Guardant Health in the second quarter worth about $345,069,000. MCF Advisors LLC grew its holdings in shares of Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock worth $26,000 after acquiring an additional 151 shares during the period. NFSG Corp purchased a new position in shares of Guardant Health during the 3rd quarter worth approximately $33,000. Jacobi Capital Management LLC bought a new position in shares of Guardant Health in the 3rd quarter worth approximately $35,000. Finally, Fulcrum Asset Management LLP bought a new position in shares of Guardant Health in the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on GH. Guggenheim raised their price objective on Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Barclays upped their target price on shares of Guardant Health from $200.00 to $220.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Rothschild & Co Redburn started coverage on shares of Guardant Health in a research note on Tuesday, September 8th. They issued a “buy” rating and a $203.00 price target for the company. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada boosted their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and an average price target of $190.88.

Guardant Health Price Performance

Guardant Health stock opened at $154.86 on Friday. Guardant Health, Inc. has a one year low of $74.55 and a one year high of $191.05. The business’s fifty day moving average is $168.83 and its 200 day moving average is $132.81. The stock has a market capitalization of $20.95 billion, a PE ratio of -42.08 and a beta of 1.67.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The business had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. Guardant Health’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.74) EPS. As a group, sell-side analysts expect that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.

Insider Activity at Guardant Health

In related news, Director Alex M. Azar II sold 826 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total transaction of $144,550.00. Following the transaction, the director owned 825 shares in the company, valued at $144,375. This represents a 50.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Darya Chudova sold 7,738 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the completion of the sale, the chief technology officer owned 70,635 shares in the company, valued at $12,573,030. This represents a 9.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 53,155 shares of company stock valued at $9,107,025. Insiders own 5.60% of the company’s stock.

About Guardant Health

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.